Vion Pharmaceuticals signs agreement with Hovon for Phase III cancer trial

Vion Pharmaceuticals has signed an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology to conduct a clinical trial of laromustine with standard remission-induction therapy in patients aged 18-65 with previously untreated acute myelogenous leukemia and high-risk myelodysplasia. The trial has been designed as a Phase III study in two parts. Part A will determine the feasibility of laromustine (Cloretazine) administration at three possible dose levels in combination with cytarabine and idarubicin. Part A will also evaluate the pharmacokinetics and the clinical efficacy of the laromustine combination. Part B is then designed to evaluate the clinical efficacy of the laromustine combination versus two cycles of cytarabine and idarubicin without laromustine with regard to clinical outcome, the complete... [read full story]